Physician profile
Richard E Blair
NPI 1407895972
$2,632.72
in general payments reported to CMS, 2019-2025
20 companies · $29.75 in 2025
The $29.75 reported for 2025 was less than what a typical Adult Medicine provider received nationally (typical 2025 total: $127).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,250 · 2020: $107 · 2021: $622 · 2022: $371 · 2023: $120 · 2024: $133 · 2025: $29.75.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $283.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $282.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $605.84 | 2019-2024 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $520.21 | 2019-2022 | |
| Amgen INC. | $263.55 | 2019-2020 | |
| Abbvie INC. | $261.94 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $178.28 | 2019-2022 | |
| Allergan, INC. | $142.35 | 2019 | |
| Idorsia Pharmaceuticals US INC | $119.70 | 2023 | Quviviq |
| Novartis Pharmaceuticals Corporation | $102.87 | 2019-2021 | |
| Lilly USA, LLC | $97.58 | 2019-2024 | Mounjaro, Zepbound |
| Amarin Pharma, INC. | $76.34 | 2019-2020 | |
| Pfizer INC. | $73.47 | 2019-2022 | |
| Glaxosmithkline, LLC. | $42.90 | 2019 | |
| Merck Sharp & Dohme LLC | $25.95 | 2019 | |
| Astellas Pharma US INC | $25.52 | 2020 | |
| Sanofi Pasteur INC. | $25.41 | 2019-2020 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lifescan, INC. | $17.17 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $15.35 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.94 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $12.02 | 2022 | |
| Gilead Sciences, INC. | $11.33 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Blair listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.